

December 2, 2022 | Issue 249

Editor's note

This note is produced every Friday by the <u>KPMG Center for Healthcare Regulatory Insight</u> and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to <u>subscribe to our mailing list here</u>.

We welcome your feedback. Let us know if KPMG can help. Please <u>reply here to me</u>, **Larry Kocot**, principal and national leader, KPMG Center for Healthcare Regulatory Insight or simply reply to this email with any comments or requests.

> Subscribe here



Healthcare regulatory news

OCR <u>proposed</u> allowing healthcare providers to share a patient's substance use treatment record after a one-time consent... OCR <u>warned</u> covered entities that they must ensure their tracking technology vendors comply with HIPAA.

CMS is seeking comment on changes to ACA essential health benefits.

FDA <u>approved</u> the <u>first gene therapy for hemophilia B</u>, the <u>most expensive single-use therapy</u> in the US (\$3.5M list price)... FDA <u>granted accelerated review of Sarepta's</u> gene therapy for Duchenne muscular dystrophy.

HRSA proposed revising the 340B administrative dispute resolution process.

HHS OIG <u>estimated Medicare paid \$42.3M for advance care planning</u> in 2019 that did not comply with federal requirements.

CDC is awarding \$3.2B to strengthen the public health workforce/infrastructure.



Healthcare law and policy news

CMS data show Medicare's Direct Contracting Model saved \$70M in 2021.

Georgia will launch Medicaid work requirements in July 2023.

Teva (\$4.25B) and Abbvie (\$2.37B) <u>finalized terms to resolve opioid-related settlements</u> with US state/local governments... Teva and Sandoz <u>plan</u> to ramp-up biosimilar production... Eisai and Biogen <u>reported</u> their Alzheimer's antibody treatment, lecanemab, <u>slowed cognitive decline</u>; however, a second clinical trial patient died from a brain hemorrhage.

AstraZeneca will acquire Neogene Therapeutics (\$320M)... Boston Scientific will acquire Apollo Endosurgery (\$615M value)... Amwell is exploring a \$200M buyout of Talkspace... Horizon Therapeutics is considering buyout offers from several pharmaceutical companies... Everstone Capital is considering selling its medical device firm, Everlife... GE announced spinoff plans for its healthcare division... Google Health will commercialize its mammography AI with iCAD... Amazon Web Services launched a genomics data service... A start-up is seeking FDA approval for an overthe-counter nasal swab version of naloxone.

Kaufman Hall reported hospitals are projected to end the year with negative operating margins, which were down 13% year-over-year in October... KFF-Peterson reported medical care price inflation (5%) was uncharacteristically lower than economy-wide inflation (7.7%) in October... KFF reported 50% of large employers offering retiree health benefits offer coverage through an MA plan, up from 26% in 2017.

A *USA Today* investigation found <u>just 4% of nursing homes violating Medicare staffing requirements</u> were cited by government inspectors.

A <u>JAMA study found</u> "skinny labeling" on biosimilars saved Medicare <u>\$1.5B from 2015-2020</u>, nearly 5% of total spending on the five biologics.

Special Section: COVID-19 and Monkeypox News

Last week, the Biden Administration <u>launched a "six week sprint" to improve uptake of COVID-19 booster shots</u>, including \$350M in funding for community health centers to establish pop-up and mobile vaccine sites and \$125M to get the vaccine to older Americans and those with disabilities... CMS <u>guidance urged nursing homes</u> to stay on top of COVID-19 vaccine boosters and treatments for staff and residents.

The Pandemic Response Accountability Committee said <u>federal program could do more to prevent</u> <u>fraud, waste, and abuse</u> associated with telehealth.

A <u>Washington Post analysis</u> of CDC data show nine out of ten COVID-19 deaths per day in the US are in people aged 65 and older.

CDC data show the updated COVID-19 bivalent booster vaccines increase individuals' protection against symptomatic infection.

FDA revoked emergency authorization for Eli Lilly's COVID-19 monoclonal antibody treatment, bebtelovimab, due to its ineffectiveness against the latest COVID-19 strains.

World Health Organization will phase out use of the term "monkeypox" and replace it with "mpox"... A UK analysis found even a single dose of the monkeypox vaccine is 78% effective against the virus 14 days or more after vaccination... The Biden Administration plans to soon issue a 60-day notice on ending the mpox public health emergency.



Questions or comments, please send to us-hcinsight@kpmg.com.

kpmg.com/socialmedia











Privacy | Legal

This email was sent by KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2022 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP295619-1A

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.